What is the recommended initial and repeat dosing of Ryanodex (dantrolene) for a 70‑kg adult with malignant hyperthermia?

Ryanodex Dosing for Malignant Hyperthermia in a 70-kg Adult

For a 70-kg adult with malignant hyperthermia, administer Ryanodex starting with an initial dose of 1 mg/kg (70 mg, or approximately 1 vial) by intravenous push, then repeat with additional 1 mg/kg boluses every 10 minutes until clinical signs resolve, up to a maximum cumulative dose of 10 mg/kg (700 mg, or approximately 3 vials). 1

Initial Dosing

The FDA-approved Ryanodex label specifies a minimum initial dose of 1 mg/kg administered by intravenous push 1. For your 70-kg patient, this translates to:

• Initial dose: 70 mg (approximately 1 vial of 250 mg Ryanodex)

This differs from the traditional dantrolene formulation dosing. The Association of Anaesthetists guidelines recommend 2-3 mg/kg for traditional dantrolene 2, but Ryanodex's FDA label explicitly states 1 mg/kg as the minimum starting dose 1.

Repeat Dosing

Administer additional 1 mg/kg boluses (70 mg each) by intravenous push if physiologic and metabolic abnormalities persist 1. The key treatment endpoints are:

• End-tidal CO₂ < 6 kPa (< 45 mmHg) with normal minute ventilation
• Core temperature < 38.5°C and decreasing
• Resolution of muscle rigidity, tachycardia, and metabolic acidosis 2

Continue dosing every 10 minutes until these goals are achieved, up to a maximum cumulative dose of 10 mg/kg (700 mg total, or approximately 3 vials) 1.

Critical Practical Considerations

Ryanodex's major advantage is rapid reconstitution: Each 250 mg vial dissolves in only 5 mL of sterile water within seconds, compared to traditional dantrolene requiring 60 mL per 20 mg vial with 5 minutes of vigorous shaking 2. This speed is lifesaving—administer each prepared syringe immediately rather than waiting to prepare the full initial dose 2.

Reconstitution Steps:

1. Add 5 mL sterile water for injection (no bacteriostatic agent) to each vial
2. Shake to create orange-colored uniform suspension
3. Use within 6 hours of reconstitution
4. Administer via IV push into running IV line or patent catheter
5. Flush line after administration 1

If Symptoms Recur (Recrudescence)

If MH signs reappear after initial control, restart dosing at 1 mg/kg by intravenous push 1. Recrudescence occurs in approximately 10-20% of cases and can happen up to 14 hours after initial resolution 2. Do not use prophylactic continuous infusion—it causes thrombophlebitis and is unnecessary in most cases 2.

Important Caveats

• Base dosing on actual body weight, not ideal body weight 2
• If cumulative dose reaches 10 mg/kg without resolution, formally reassess the diagnosis but continue dantrolene if MH remains likely, despite the product label maximum 2
• The 1 mg/kg Ryanodex dosing is lower than the 2-3 mg/kg recommended for traditional dantrolene formulations, reflecting differences in the FDA-approved labeling between products 1 versus guideline recommendations 2
• Monitor for muscle weakness, dysphagia, respiratory compromise, somnolence, and dizziness post-administration 1